Research statistics

Semaglutide research: publications and trials

What has been published on Semaglutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Semaglutide works or is safe. For what it is and what the studies found, see the Semaglutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

4,968

Since 2012

Publications in 2026 so far

1,707

Through November 15, 2026

Human clinical research

40.2%

1,979 of 4,922 classified

Registered clinical trials

658

ClinicalTrials.gov

Randomized controlled trials

372

Publications reporting an RCT in people

Systematic reviews and meta-analyses

446

Preclinical studies

14.3%

450 animal · 88 in vitro · 164 computational

Records that only mention it

642

Not counted above

Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 46 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Semaglutide publications by year and evidence

2012, Reviews and meta-analyses: 1 of 12013, Reviews and meta-analyses: 1 of 12014, Preclinical (animal, in vitro, computational): 1 of 32014, Reviews and meta-analyses: 1 of 32014, Other and not yet classified: 1 of 32015, Human clinical research: 2 of 32015, Preclinical (animal, in vitro, computational): 1 of 32016, Human clinical research: 2 of 102016, Reviews and meta-analyses: 6 of 102016, Other and not yet classified: 2 of 102017, Human clinical research: 13 of 562017, Preclinical (animal, in vitro, computational): 1 of 562017, Reviews and meta-analyses: 27 of 562017, Other and not yet classified: 15 of 562018, Human clinical research: 22 of 942018, Preclinical (animal, in vitro, computational): 9 of 942018, Reviews and meta-analyses: 54 of 942018, Other and not yet classified: 9 of 942019, Human clinical research: 26 of 942019, Preclinical (animal, in vitro, computational): 13 of 942019, Reviews and meta-analyses: 35 of 942019, Other and not yet classified: 20 of 942020, Human clinical research: 32 of 1192020, Preclinical (animal, in vitro, computational): 19 of 1192020, Reviews and meta-analyses: 56 of 1192020, Other and not yet classified: 12 of 1192021, Human clinical research: 55 of 1872021, Preclinical (animal, in vitro, computational): 27 of 1872021, Reviews and meta-analyses: 59 of 1872021, Other and not yet classified: 46 of 1872022, Human clinical research: 76 of 2212022, Preclinical (animal, in vitro, computational): 50 of 2212022, Reviews and meta-analyses: 74 of 2212022, Other and not yet classified: 21 of 2212023, Human clinical research: 147 of 3702023, Preclinical (animal, in vitro, computational): 63 of 3702023, Reviews and meta-analyses: 80 of 3702023, Other and not yet classified: 80 of 3702024, Human clinical research: 327 of 8142024, Preclinical (animal, in vitro, computational): 113 of 8142024, Reviews and meta-analyses: 200 of 8142024, Other and not yet classified: 174 of 8142025, Human clinical research: 559 of 1,2882025, Preclinical (animal, in vitro, computational): 172 of 1,2882025, Reviews and meta-analyses: 304 of 1,2882025, Other and not yet classified: 253 of 1,2882026 (to date), Human clinical research: 718 of 1,7072026 (to date), Preclinical (animal, in vitro, computational): 233 of 1,7072026 (to date), Reviews and meta-analyses: 544 of 1,7072026 (to date), Other and not yet classified: 212 of 1,707Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05001,0001,5002,00020122015201820212026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
201200101
201300101
201401113
201521003
2016206210
2017131271556
201822954994
20192613352094
202032195612119
202155275946187
202276507421221
2023147638080370
2024327113200174814
20255591723042531,288
2026 (to date)7182335442121,707

Study types

Observational human study1,165
Review996
Editorial, letter or other783
Animal study450
Randomized controlled trial372
Case report328
Meta-analysis255
Systematic review191
Computational study164
Other clinical trial114
In vitro study88
Not yet classified46
Guideline or consensus16

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health3,363
Obesity and weight management2,074
Endocrinology1,887
Cardiovascular948
Gastrointestinal581
Neurological and mental health518
Immune system228
Reproductive and sexual health206
Musculoskeletal157
Oncology106
Cognitive health96
Dermatology82

Registered clinical trials

102 of 281 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 320 · Recruiting: 138 · Not yet recruiting: 79 · Active, not recruiting: 55 · Unknown status: 35 · Enrolling by invitation: 11 · Withdrawn: 11 · Terminated: 8 · Suspended: 1
Early phase 1: 5 · Phase not applicable: 135 · Phase 1: 117 · Phase 1 / Phase 2: 8 · Phase 2: 112 · Phase 2 / Phase 3: 12 · Phase 3: 161 · Phase 4: 108

TrialStatusPhaseStartedResults
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)NCT07586150 · 140 enrolledNot yet recruitingPhase not applicable2028-10—
GLP-1 RA for Stage 1 Type 1 DiabetesNCT07430332 · 15 enrolledNot yet recruitingPhase 22027-09—
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes MellitusNCT07797036 · 226 enrolledNot yet recruitingPhase 2, Phase 32027-09—
Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerNCT07909889 · 32 enrolledNot yet recruitingPhase 22027-03—
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent ObesityNCT07911046 · 12 enrolledNot yet recruitingPhase not applicable2027-03—
Semaglutide for Low Back PainNCT07731256 · 250 enrolledNot yet recruitingPhase 22027-02—
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05714683 · 600 enrolledNot yet recruitingPhase not applicable2027-01—
Semaglutide for the Treatment of Cannabis Use DisorderNCT07879612 · 40 enrolledNot yet recruitingPhase 22027-01—
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerNCT07462663 · 80 enrolledNot yet recruitingPhase 42027-01—
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.NCT07614412 · 240 enrolledNot yet recruitingPhase 22027-01—
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial CancerNCT07820358 · 48 enrolledNot yet recruitingPhase 22027-01—
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant AccessNCT07858331 · 880 enrolledNot yet recruitingPhase 42027-01—
Validation & Intervention Testing for Aging, Longevity and HealthspanNCT07923630 · 1,200 enrolledNot yet recruitingPhase 22027-01—
Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy AdultsNCT07935200 · 44 enrolledNot yet recruitingPhase 12027-01—
Semaglutide for the Prevention Of Post-Transplant Diabetes MellitusNCT06913023 · 37 enrolledNot yet recruitingPhase 2, Phase 32026-12—
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyNCT07642635 · 30 enrolledRecruitingPhase 1, Phase 22026-12—
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic SyndromeNCT07770282 · 600 enrolledNot yet recruitingPhase 32026-12—
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNCT06977438 · 1,020 enrolledNot yet recruitingPhase 42026-11—
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNCT07919405 · 1,408 enrolledNot yet recruitingPhase 32026-11—
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNCT07931573 · 1,200 enrolledNot yet recruitingPhase 32026-11—
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNCT07931599 · 1,060 enrolledNot yet recruitingPhase 32026-11—
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver DiseaseNCT06546384 · 64 enrolledNot yet recruitingPhase not applicable2026-11—
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsNCT07845994 · 50 enrolledNot yet recruitingPhase 32026-11—
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke ThrombectomyNCT07511543 · 100 enrolledNot yet recruitingPhase 22026-10—
Mechanisms of Weight Loss: Tirzepatide vs SemaglutideNCT07900074 · 80 enrolledRecruitingPhase 42026-10—
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes MellitusNCT07923357 · 364 enrolledNot yet recruitingPhase 22026-10—
Translational Health Research Into Vascular and Neurocognitive Effects of Weight LossNCT07592546 · 240 enrolledRecruitingPhase 42026-10—
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsNCT07840729 · 90 enrolledRecruitingPhase 12026-10—
Semaglutide in Youth With Autism Spectrum DisorderNCT07770152 · 42 enrolledRecruitingPhase 42026-10—
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNCT07866066 · 1,300 enrolledRecruitingPhase 32026-10—
Long-Term Effects of Semaglutide on Body Composition and Performance in RunningNCT07874932 · 41 enrolledNot yet recruitingPhase not applicable2026-10—
Short Term Effects of Semaglutide on Body Composition and PerformanceNCT07874971 · 41 enrolledNot yet recruitingPhase not applicable2026-10—
Semaglutide Health Outcomes and Patient Adherence in AustraliaNCT07881770 · 10,000 enrolledNot yet recruitingPhase not applicable2026-10—
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.NCT07891156 · 40 enrolledRecruitingPhase 2, Phase 32026-10—
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)NCT07812597 · 210 enrolledNot yet recruitingPhase 22026-10—
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaNCT07900438 · 300 enrolledRecruitingPhase 42026-10—
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerNCT07627191 · 30 enrolledRecruitingEarly phase 12026-10—
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationNCT07855133 · 60 enrolledRecruitingPhase 12026-10—
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial FibrillationNCT07389941 · 240 enrolledNot yet recruitingPhase 42026-10—
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesNCT07772960 · 90 enrolledRecruitingPhase 12026-10—
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNCT07859137 · 100 enrolledNot yet recruitingPhase 42026-10—
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150 · 104 enrolledNot yet recruitingPhase 42026-10—
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163 · 100 enrolledNot yet recruitingPhase 42026-10—
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176 · 100 enrolledNot yet recruitingPhase 42026-10—
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNCT07859189 · 100 enrolledNot yet recruitingPhase 42026-10—
FutureShape FamilyNCT07872904 · 400 enrolledRecruitingPhase 42026-10—
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500 · 660 enrolledRecruitingPhase 32026-09—
A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightNCT07845578 · 60 enrolledNot yet recruitingPhase 12026-09—
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 · 650 enrolledRecruitingPhase 32026-09—
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumNCT06073184 · 71 enrolledRecruitingPhase 22026-09—

The 50 most recently started of 658 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Exploring time-varying cardiovascular effects of GLP-1 receptor agonists: A multi-state network meta-analysis of cardiovascular outcome trials.

    Diabetes research and clinical practice · November 6, 2026 · Meta-analysis · cited 0 times

    PMID 42994759 · DOI 10.1016/j.diabres.2026.113638 · Reviews and meta-analyses

  2. Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.

    Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times

    PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses

  3. Glucagon-like peptide-1 receptor agonists and risk of arrhythmias: A network meta-analysis.

    Heart rhythm · October 26, 2026 · Meta-analysis · cited 0 times

    PMID 42933519 · DOI 10.1016/j.hrthm.2026.10.052 · Reviews and meta-analyses

  4. Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis.

    European journal of clinical pharmacology · October 24, 2026 · Meta-analysis · cited 0 times

    PMID 42920001 · DOI 10.1007/s00228-026-04206-4 · Reviews and meta-analyses

  5. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

    Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses

  6. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.

    Medicine · October 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42937793 · DOI 10.1097/md.0000000000051306 · Reviews and meta-analyses

  7. Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.

    Clinical obesity · October 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42584177 · DOI 10.1111/cob.70105 · Reviews and meta-analyses

  8. Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.

    Clinical obesity · October 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42670242 · DOI 10.1111/cob.70111 · Reviews and meta-analyses

  9. Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.

    International journal of obesity (2005) · September 28, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42806056 · DOI 10.1038/s41366-026-02229-6 · Reviews and meta-analyses

  10. GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.

    Drugs · September 26, 2026 · Meta-analysis · cited 0 times

    PMID 42791433 · DOI 10.1007/s40265-026-02380-4 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

    The New England journal of medicine · September 15, 2016 · Randomized controlled trial · cited 6,867 times · open access

    PMID 27633186 · DOI 10.1056/nejmoa1607141 · Human clinical research

  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity.

    The New England journal of medicine · February 10, 2021 · Randomized controlled trial · cited 5,142 times · open access

    PMID 33567185 · DOI 10.1056/nejmoa2032183 · Human clinical research

  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

    The New England journal of medicine · November 11, 2023 · Randomized controlled trial · cited 3,168 times · open access

    PMID 37952131 · DOI 10.1056/nejmoa2307563 · Human clinical research

  4. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    The New England journal of medicine · June 25, 2021 · Randomized controlled trial · cited 2,072 times · open access

    PMID 34170647 · DOI 10.1056/nejmoa2107519 · Human clinical research

  5. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

    The New England journal of medicine · November 13, 2020 · Randomized controlled trial · cited 2,024 times · open access

    PMID 33185364 · DOI 10.1056/nejmoa2028395 · Human clinical research

Latest publications

  1. Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review.

    BMC oral health · November 14, 2026 · Systematic review · cited 0 times

    PMID 43034163 · DOI 10.1186/s12903-026-10305-6 · Reviews and meta-analyses

  2. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.

    The lancet. Diabetes & endocrinology · November 14, 2026 · Not yet classified · cited 0 times

    PMID 43033821 · DOI 10.1016/s2213-8587(26)00275-5 · Not yet classified

  3. Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide.

    Nature metabolism · November 13, 2026 · Not yet classified · cited 0 times

    PMID 43026316 · DOI 10.1038/s42255-026-01661-2 · Not yet classified

  4. Weight loss at a cost: Semaglutide and PYY3-36 aggravate pre-existing metabolic osteoporosis in female Wistar rats.

    Bone · November 13, 2026 · Animal study · cited 0 times

    PMID 43025770 · DOI 10.1016/j.bone.2026.118170 · Animal studies

  5. Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks.

    Minerva endocrinology · November 13, 2026 · Review · cited 0 times

    PMID 43021748 · DOI 10.23736/s2724-6507.26.04655-5 · Reviews and meta-analyses

  6. GLP-1 dose escalation and disputed ignition interlock alcohol results: Case report.

    The Medico-legal journal · November 12, 2026 · Case report · cited 0 times · open access

    PMID 43018099 · DOI 10.1177/00258172261476035 · Human clinical research

  7. GLP-1-based Therapies in MASH: From Metabolic Benefits to an Improvement in Liver Fibrosis.

    Internal medicine (Tokyo, Japan) · November 12, 2026 · Review · cited 0 times

    PMID 43014742 · DOI 10.2169/internalmedicine.8562-26 · Reviews and meta-analyses

  8. Gut-hormone receptor systems in the eye: Pharmacological, local and putative endocrine signalling.

    European journal of ophthalmology · November 11, 2026 · Review · cited 0 times · open access

    PMID 43012562 · DOI 10.1177/11206721261507148 · Reviews and meta-analyses

  9. Follow-up discrepancies in a TriNetX-based comparison of preoperative tirzepatide or semaglutide use and postoperative total hip/knee arthroplasty outcomes.

    European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · November 11, 2026 · Editorial, letter or other · cited 0 times

    PMID 43012889 · DOI 10.1007/s00590-026-05030-3 · Commentary and other

  10. Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide.

    Nature metabolism · November 11, 2026 · Observational human study · cited 0 times

    PMID 43015368 · DOI 10.1038/s42255-026-01656-z · Human clinical research

Browse all 4,968 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Kayshild; NN9535; NN9536; NN9924; Ozempic; Rybelsus; Semaglutide; Wegovy

((TITLE_ABS:"Kayshild" OR CHEM:"Kayshild") OR (TITLE_ABS:"NN9535" OR CHEM:"NN9535" OR TITLE_ABS:"NN 9535" OR CHEM:"NN 9535") OR (TITLE_ABS:"NN9536" OR CHEM:"NN9536" OR TITLE_ABS:"NN 9536" OR CHEM:"NN 9536") OR (TITLE_ABS:"NN9924" OR CHEM:"NN9924" OR TITLE_ABS:"NN 9924" OR CHEM:"NN 9924") OR (TITLE_ABS:"Ozempic" OR CHEM:"Ozempic") OR (TITLE_ABS:"Rybelsus" OR CHEM:"Rybelsus") OR (TITLE_ABS:"Semaglutide" OR CHEM:"Semaglutide") OR (TITLE_ABS:"Wegovy" OR CHEM:"Wegovy")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Semaglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/semaglutide